Market Research Reports

Non Small Cell Lung Cancer Market - Global Industry Size, Share, Trends, Analysis And Forecasts 2012 - 2018

 

Description


Description

Globally, the Non-Small-Cell Lung Cancer (NSCLC) drug market will increase from USD 4.3 billion in 2009 to USD 6.9 billion in 2019 and the market is growing with a CAGR of 4.84% during 2009 to 2019. The major markets in these segments are the United States, France, Germany, Italy, Spain, United Kingdom and Japan. The global top five global brands in NSCLC with the largest market share are Avastin, Tarceva, Alimta, Gemzar and Taxotere. For growth in the future there are drugs in the pipeline and in clinical trials at the phase 3 process development in the non small cell lung cancer market.
 
In the year 2012 many pipeline agents are going to be launched - such as Stimuvax and Aflibercept. The drugs that are in clinical trials phase 3 processes are vargatef (BIBF 1120), BIBW 2992, Crizotinib, Erbitux, ARQ 197, and Ramucirumab. In the NSCLC drug market, clinical trials have been discontinued due to the failure to meet the primary endpoint of overall survival in phase III non small cell lung cancer such as Nexavar, Sutent, AMG-706, Zactima, Figitumumab, ASA-404, 
The high growth forecast is primarily attributed to the strong pipeline landscape, population growth and release of new first-in-class drugs with better safety and efficacy profiles. The NSCLC drugs market will grow due to smoking, secondary lifestyle, and other agents such as asbestos and radon, and air pollution. 

The Indian non-small-cell lung cancer drug market will almost double by 2013, growing from USD 27.7 billion in 2008 to USD 52.1 billion in 2013. This growth will be fueled by an increased uptake of antimetabolites and targeted therapies. In fact, the epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) inhibitor drug classes will dominate the market throughout the forecast period with a combined market share of 55 percent by 2013. The India non-small-cell lung cancer drug market CAGR will be 13.47% from 2008-2015. 

The NSCLC drug market will continue to move toward personalized medicine through 2019, resulting in an increasingly fragmented market. The findings also reveal that in 2009, Alimta and Tarceva and Roche/Genentech/Chugai’s Avastin were the leading therapies in NSCLC, capturing nearly two-thirds of overall sales. Through 2019, Alimta and Tarceva-which are increasingly being used in the first-line setting, and also as maintenance therapies will continue to dominate the market, as will Avastin, which will maintain steady uptake.

The new emerging markets of non-small-cell lung cancer have increased penetration of current targeted therapies and the big players in this market are AstraZeneca’s Roche’s and Merck KGaA’s. These manufacturers are the main driving force in the global non-small-cell lung cancer market from 2009 to 2017. 

Table of Contents


 

Enquiry Before Buying


 
Pre Book Price: $4315.5 Original Price: $4795
Share This Market Study!  

Upcoming Report

Payment
Copyright @ Transparency Market Research